Global Paediatric Vaccine Industry Set for Explosive Growth at 13.1% CAGR, Reaching US$184.7 Billion by 2033 | FMI Analysis

Global Paediatric Vaccine Industry
Global Paediatric Vaccine Industry

The Global Paediatric Vaccine Industry is on the cusp of a remarkable surge, according to a recent analysis by [Your Company Name]. The market, currently valued at an estimated US$54.13 billion in 2023, is projected to skyrocket at a phenomenal Compound Annual Growth Rate (CAGR) of 13.1% from 2023 to 2033. This translates to a staggering market valuation of US$184.7 billion by 2033.

This substantial expansion underscores the increasing importance and demand for paediatric vaccines worldwide. The burgeoning market is driven by advancements in medical research, a focus on preventive healthcare, and a growing awareness of the importance of immunization for children’s well-being.

A slew of routine immunisation initiatives rolled out by the government and private agencies have broadened the market for paediatric vaccines. A new wave of funds pumped into the market by different government and private players to curb the rise of child deaths across the globe has also opened a new window of opportunity for the paediatric vaccine market. As per the report of WHO (World Health Organization), global spending on immunisation soared from US$21.4 to US$26.9 per infant in 2014. The massive economic boom in some regions of the world is expediting the growth of the paediatric vaccine market.

Request Sample Copy of the Latest Reports
https://www.futuremarketinsights.com/reports/sample/rep-gb-1317

Segmentation analysis

  • By indication, the pneumococcal segment accounted for a higher revenue share in global paediatric vaccines as compared to other product segments. The pneumococcal segment is expected to reach a value of US$ 31.58 Bn by 2026, reflecting a CAGR of 14.4% over the forecast period. The growth of the pneumococcal segment is attributed to the increasing incidence of infectious diseases.
  • In terms of revenue, the Hib vaccine segment is the second most growing segment and is expected to reach a value of US$ 13.49 Bn by 2026, growing at a CAGR of 13.4%. The hepatitis B and meningococcal segments are expected to show double-digit CAGR growth in the forecast period contributing to the growth of the global paediatric vaccine market.
  • By technology, the conjugate segment accounted for the highest revenue share in the global paediatric vaccine market as compared to the live or attenuated segment. The conjugate segment is expected to reach a value of US$ 32.09 Bn by 2026, reflecting a CAGR of 14.8% over the forecast period. This is expected to be closely followed by the growth of pneumococcal and meningococcal vaccines in this segment
  • By end user, institutional health centres account for higher demand for paediatric vaccines as compared to other end-user segments such as hospital pharmacies and retail pharmacies. The strong growth in institutional health centres can be attributed to increasing government interventions in immunisation programs to improve vaccine coverage. Institutional health centres are expected to register the highest CAGR of 13.8% over the forecast period.

Regional analysis

By region, North America is dominating the global paediatric vaccine market due to improved healthcare infrastructure in this region. The North American paediatric vaccine market is expected to be valued at US$ 20.15 Bn by 2026 growing at a CAGR of 11.0%. In addition to North America, demand for paediatric vaccines has been significantly growing in Western Europe and APEJ. APEJ is expected to grow at a CAGR of 14.9% over the forecast period and is expected to dominate the market by 2026 by generating revenue of US$ 22.69 Bn and revenues in Western Europe are anticipated to grow by 11.2%. Middle East and Africa are expected to grow at a CAGR of 12.6% and this growth is anticipated by growth government intervention for immunisation by carrying out national-level immunisation campaigns and also disease-specific immunisation campaigns.

Key players in the global paediatric vaccine market include

  • Indian Immunologicals,
  • GlaaxoSmithKline Plc.,
  • Pfizer Inc.,
  • Sanofi, Merck & Co. Inc.,
  • Panacea Biotec,
  • Zydus Cadila,
  • Emergent BioSolutions Inc.,
  • Serum Institute of India Pvt. Ltd.,
  • Bharat Biotech.

The growth of the paediatric vaccine market is attributed to the development in the research by key players in the field, for instance, in February 2016, GSK submitted a US regulatory submission for expanding the indication of FLuLaval Quadrivalent, an influenza vaccine, for infants more than 6 months. These developments will boost the growth of the global paediatric vaccine market.

Buy The Full Report Now!
https://www.futuremarketinsights.com/checkout/1317

Global Paediatric Vaccine Industry Segmentation

Technology

  • Live or Attenuated Vaccine
  • Inactivated or Killed Vaccine
  • Toxoid Vaccine
  • Conjugate Vaccine
  • Subunit Vaccine
  • Recombinant Vector Vaccine

Indication

  • Pneumococcal Conjugate Vaccine
  • DTP Vaccine
  • Influenza
  • Meningococcal Vaccine
  • Polio Vaccine
  • Rotavirus Vaccine
  • MMR Vaccine
  • Varicella Virus Vaccine

End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Health Centres

Vaccine Type

  • Monovalent Vaccines
  • Multivalent Vaccines

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these